VivoSeq
Other

Albuminuria

35

Pipeline Programs↗

2

Active Trials↗

23

Companies Involved↗

Albuminuria is a moderately active landscape with 35 programs across 23 companies. The most active players are Daiichi Sankyo, Speedel Pharma Ltd., Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 16 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

6/100

Mech. Concentration

14/100

Completion Rate

85/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 2S

Speedel Pharma Ltd.

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

1 program

Phase 2Novo Nordisk logo

Novo Nordisk

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

95%

Small molecule

38 of 40 classified programs — the dominant modality here.

5%ALL OTHERSMonoclonal antibody13%Peptide13%

Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 98% of 42 pipeline programs.

Analysis

Trial Status

35

clinical trials

Completed22 · 63%
Unknown status7 · 20%
Terminated3 · 9%
Withdrawn1 · 3%
Recruiting1 · 3%
Not yet recruiting1 · 3%

Clinical Trials

Trial Activity

35 trials

Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes
Recruiting·UUniversity of Colorado, Denver·Approved·NCT05498116·50 enrolled
Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Not yet recruiting·FFirst Affiliated Hospital of Zhejiang University·Approved·NCT07667517·148 enrolled
Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
Completed·SSteno Diabetes Center Copenhagen·Phase 4·NCT00320879·52 enrolled
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Completed·AbbVie logoAbbVie·Phase 2·NCT01356849·149 enrolled
VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With Microalbuminuria
Completed·Novartis logoNovartis·Phase 3·NCT00171067·134 enrolled
SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)
Completed·TTheravia·Phase 2·NCT03806452·86 enrolled
Shiga Microalbuminuria Reduction Trial-2
Completed·SShiga University·Phase 4·NCT01461499·237 enrolled
The Effect of Folic Acid Administration in the Progression of Microalbuminuria
Completed·HHospital Universitario Dr. Jose E. Gonzalez·N/A·NCT00737126·40 enrolled
Chicken-Diet vs. Enalapril to Reduce Albuminuria
Completed·HHospital de Clinicas de Porto Alegre·N/A·NCT00484068·28 enrolled
A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria
Completed·Daiichi Sankyo logoDaiichi Sankyo·Phase 2·NCT02345057·365 enrolled
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
Completed·UUniversity Health Network, Toronto·Phase 4·NCT02585804·10 enrolled
Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria
Completed·OOslo University Hospital·Phase 3·NCT01694160·77 enrolled
Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria
Completed·SSpeedel Pharma Ltd.·Phase 2·NCT00561171·50 enrolled
Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria
Completed·Sanofi logoSanofi·Phase 3·NCT00561964·241 enrolled
Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria
Completed·Sanofi logoSanofi·Phase 4·NCT00334581·192 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)